<DOC>
	<DOC>NCT02297139</DOC>
	<brief_summary>The purpose of this study is to continue to provide dasatinib to patients that are currently participating in another dasatinib trial that is ending and for which there is no other option to provide dasatinib.</brief_summary>
	<brief_title>Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib</brief_title>
	<detailed_description />
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Participated in and completed a previous dasatinib protocol (including but not limited to CA180056, CA180363 or CA180227) and is deemed by the investigator to be deriving benefit from dasatinib as defined by the previous protocol Receiving dasatinib at the time of signature of informed consent Males and Females, ages 18 and older All patients previously discontinued from a dasatinib study for any reason Any serious or uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy History of allergy to dasatinib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>